Physician Education: Bridging Clinical Research and Patient Care

IAS-USA Board of Directors Disclosure Information

In the interest of maintaining the independence of its continuing medical education (CME) activities, and in accordance with the policies of the Accreditation Council for Continuing Medical Education (ACCME), the IAS–USA requires all persons with control of content (ie, faculty, IAS–USA Board members, and program staff) to disclose any financial relationships that they or their spouses or partners have had with commercial companies within the past 12 months. Any real or apparent conflicts of interest of those parties are resolved prior to the CME activity being delivered. Individuals who refuse to disclose financial interests may not participate in an IAS–USA CME activity.

IAS–USA Board of Directors

Constance A. Benson, MD
Dr Benson serves on a data and safety monitoring board for GlaxoSmithKline/ViiV Healthcare. She has received research grants awarded to the University of California San Diego from Gilead Sciences, Inc and ViiV Healthcare. Disclosure information for her spouse, Robert T. Schooley, MD, is indicated below. (Updated 04/26/15)

Peter Cassat, JD
Mr Cassat has no relevant financial affiliations to disclose. (Updated 05/30/12)

Judith S. Currier, MD
Dr Currier has no relevant financial affiliations to disclose. (Updated 05/12/16)

Carlos del Rio, MD
Dr del Rio has served as a consultant for InnaVirVax.  (Updated 08/15/16)

Joel E. Gallant, MD, MPH
Dr Gallant has served as a consultant or advisor to Bristol-Myers Squibb, Gilead Sciences, Inc, Janssen Therapeutics, Merck & Co, Inc, and ViiV Healthcare. He has received research grants or contracts awarded to his institution from AbbVie, Bristol-Myers Squibb, Gilead Sciences, Inc, Janssen Therapeutics, Inc, Merck & Co, Inc, Sangamo BioSciences, and ViiV Healthcare. (Updated 03/16/16)

Roy M. Gulick, MD, MPH
Dr Gulick has no relevant financial affiliations to disclose. (Updated 03/16/16)

Donna M. Jacobsen
Ms Jacobsen has no relevant financial affiliations to disclose. (Updated 08/23/16)

Jeanne M. Marrazzo, MD, MPH
Dr Marrazzo has received has received research support from Cepheid and Merck & Co, Inc, and has served as a consultant for Cepheid. (Updated 04/10/2016)

Douglas D. Richman, MD
Dr Richman has been a consultant to Antiva Biosciences, Chimerix, Gilead Sciences, Inc, and Monogram Biosciences, Inc. (Updated 06/15/16)

Michael S. Saag, MD
Dr Saag has received grants and research support from Bristol-Myers Squibb, AbbVie, Merck & Co, Inc, Gilead Sciences, Inc, and ViiV Healthcare. He has served as a scientific advisor to Bristol-Myers Squibb, Merck & Co, Inc, Gilead Sciences, Inc, and Teva Pharmaceuticals. (Updated 08/11/16)

Robert T. Schooley, MD
Dr Schooley was awarded research grants, paid to his institution, from Boehringer Ingelheim Pharmaceuticals, Inc, and Bristol-Myers Squibb. His institution has received payment for his consultative advice and/or data monitoring committee service from GlobeImmune, Gilead Sciences, Inc, and Monogram Biosciences. He serves as a consultant to CytoDyn, HERA Therapeutics and Farmak and has stock options from CytoDyn, HERA Therapeutics and GlobeImmune. (Updated 09/01/15)

Paul A. Volberding, MD
Dr Volberding has served on data safety monitoring boards for Merck & Co, Inc. (Updated 08/04/16)